April 13, 2026 - 23:13

Investors often flock to stocks with low price-to-earnings (P/E) ratios, seeing them as undervalued bargains. However, a superficial glance at Micron Technology's earnings multiples could lead to a misleading conclusion about its true value. The memory chip sector, where Micron is a leader, is notoriously cyclical, experiencing dramatic swings between periods of soaring profitability and steep losses.
During an industry upswing, earnings explode, making the P/E ratio appear attractively low. Conversely, in a downturn, earnings can vanish or turn negative, rendering the P/E ratio meaningless or sky-high. Therefore, judging Micron solely on its current P/E is an incomplete analysis. It captures only a single moment in a volatile cycle rather than the company's long-term earnings power.
A more nuanced approach is required. Analysts emphasize evaluating memory stocks like Micron based on the price-to-book ratio or by examining normalized earnings over a full industry cycle. These metrics help smooth out the cyclical extremes. Furthermore, investors must consider the capital-intensive nature of the business, requiring massive, continuous investment in new fabrication plants. While Micron's innovation in high-bandwidth memory for AI is a strong tailwind, the core DRAM and NAND markets remain subject to the laws of supply and demand. The stock's valuation is a complex puzzle where today's earnings are just one piece, not the entire picture.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...